Pharmaceutical Patent Strategies and Market Dynamics

Pharmaceutical innovators rely on a complex web of patent strategies to secure exclusive rights, manage product lifecycles and maximise revenues, while regulators and competitors navigate legal and economic levers to promote timely generic or biosimilar entry. Primary patents, covering novel active molecules, are often supplemented by secondary or “evergreening” patents on formulations, dosages, isomers or delivery methods to extend monopoly periods. Patent linkage mechanisms and data exclusivity regimes further delay market entry of competitors, affecting drug prices and patient access. At the same time, trade agreements embed TRIPS-plus provisions that can strengthen monopolies, whereas TRIPS flexibilities such as compulsory licensing and parallel importation aim to balance public health needs. Recent research has illuminated how these strategies interact, from regional patent-linkage impacts on generic approvals to innovative proposals for benevolent patent extensions that channel extra revenues into research for low- and middle-income countries.

Research from Nature Portfolio

Recent studies have proposed “benevolent” patent extensions, whereby innovators receive additional patent term in highly profitable markets in exchange for directing R&D efforts towards vaccines, agricultural inputs or other non-essential innovations that serve low- and middle-income nations. Modelling suggests that such extensions could unlock billions of dollars for global health research without undermining core incentives for novel drug discovery. This approach reframes life-cycle management by linking extended exclusivity to clearly defined social benefits, offering a potential pathway to reconcile commercial interests with broader public-health goals.

Pharmaceutical Patent Strategies and Market Dynamics publication trend

The graph below shows the total number of articles in pharmaceutical patent strategies and market dynamics across all publications each year (not limited to Nature Index journals).

Technical terms

Evergreening: Strategic filing of successive patents on minor drug modifications to extend market exclusivity beyond the primary patent term.

TRIPS flexibilities: Provisions under the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights allowing measures such as compulsory licensing and parallel importation to promote public health.

Secondary patent: A patent claim covering aspects of a known compound—such as formulation, method of use or polymorph—filed to prolong exclusivity.

Patent linkage: A regulatory mechanism linking drug approval for generics to the patent status of the reference product, often delaying market entry of competitors.

References

1. ‘Benevolent’ patent extensions could raise billions for R&D in poorer countries. Nature (2023).
2. Paucity of intellectual property rights information in the US biologics system a decade after passage of the Biosimilars Act. PLOS Medicine (2024).
3. What is the impact of intellectual property rules on access to medicines? A systematic review. Globalization and Health (2022).
4. Polymorphs and Prodrugs and Salts (Oh My!): An Empirical Analysis of “Secondary” Pharmaceutical Patents. PLOS ONE (2012).
5. Patent challenges and factors associated with successful patent challengers under the patent linkage system: recent evidence from South Korea after the Korea United States free trade agreement. Globalization and Health (2021).